Is it a Prudent Move to Retain MYGN Stock in Your Portfolio Now?

Myriad Genetics (MYGN) shares have fallen 74.5% over the past year, significantly underperforming the market, despite exceeding earnings estimates in three of the last four quarters with an average surprise of 210%. The genetic testing firm is driving growth through expanded oncology offerings, including the Precise MRD test and updated NCCN guidelines for Prolaris, alongside new prenatal and tumor screening product launches. However, the company faces considerable headwinds from macroeconomic pressures, such as inflation and potential tariffs, and intensifying competition, which are projected to result in flat 2025 earnings and a 1.9% revenue decline to $821.7 million.

Analysis

Myriad Genetics (MYGN) presents a stark contrast between its strategic pipeline and its current market performance and financial outlook. The company's stock has severely underperformed, declining 74.5% over the past year against an industry drop of 13.5%, despite a history of beating earnings estimates with an average surprise of 210% in the last four quarters. This disconnect is largely explained by significant headwinds. On the positive side, Myriad is pursuing growth through its Oncology business, highlighted by the development of its Precise MRD monitoring test, which showed promising results in a Lancet Oncology-published study, and the inclusion of its Prolaris test in updated NCCN guidelines. Furthermore, a series of recent and upcoming product launches, including the FirstGene prenatal screen and the Precise Tumor assay, demonstrate a commitment to innovation. However, these developments are overshadowed by material risks. The company faces persistent macroeconomic pressures from inflation on labor and supply costs, and potential U.S. tariffs. More critically, intensifying competition threatens to erode pricing power and margins. This challenging environment is reflected in forward-looking estimates, with the Zacks Consensus Estimate for 2025 revenue pegged at $821.7 million, a projected 1.9% year-over-year decline, and flat earnings estimates, signaling that the market does not expect the current pipeline to translate into near-term growth.

Key Decisions for Investors

• Investors should weigh the potential long-term value in Myriad's innovative oncology and prenatal testing pipeline against the significant near-term risks of margin compression from competition and inflationary cost pressures.
• The forecast for a 1.9% revenue decline and flat earnings in 2025 provides a clear justification for the stock's recent underperformance, warranting caution until there are signs of a turnaround in top-line growth or market share gains.
• Given the stock's 74.5% price decline, any potential position should be considered high-risk, with key catalysts to monitor being the commercial traction of new products like FirstGene and the company's ability to defend pricing in its core markets.
• Consider the stock's 'Hold' rating and severe underperformance as a signal that the market is currently prioritizing macroeconomic and competitive headwinds over the company's history of earnings beats and pipeline developments.